SYK and glomerulonephritis: SIGN (Syk Inhibitor in GlomeruloNephritis) is a currently open phase 2 randomized, double-blind, placebo-controlled trial that is examining the efficacy of fostamatinib, an oral selective Syk inhibitor, in IgAN (ClinicalTrials.gov Identifier: NCT02112838).